Development of human umbilical cord matrix stem cell-based gene therapy for experimental lung tumors.

Department of Anatomy and Physiology, Kansas State University, Manhattan, KS 66506-5602, USA.
Cancer Gene Therapy (Impact Factor: 2.55). 11/2007; 14(10):828-35. DOI: 10.1038/sj.cgt.7701077
Source: PubMed

ABSTRACT Umbilical cord matrix stem (UCMS) cells are unique stem cells derived from Wharton's jelly, which have been shown to express genes characteristic of primitive stem cells. To test the safety of these cells, human UCMS cells were injected both intravenously and subcutaneously in large numbers into severe combined immunodeficiency (SCID) mice and multiple tissues were examined for evidence of tumor formation. UCMS cells did not form gross or histological teratomas up to 50 days posttransplantation. Next, to evaluate whether UCMS cells could selectively engraft in xenotransplanted tumors, MDA 231 cells were intravenously transplanted into SCID mice, followed by intravenous transplantation of UCMS cells 1 and 2 weeks later. UCMS cells were found near or within lung tumors but not in other tissues. Finally, UCMS cells were engineered to express human interferon beta--designated 'UCMS-IFN-beta'. UCMS-IFN-beta cells were intravenously transplanted at multiple intervals into SCID mice bearing MDA 231 tumors and their effect on tumors was examined. UCMS-IFN-beta cells significantly reduced MDA 231 tumor burden in SCID mouse lungs indicated by wet weight. These results clearly indicate safety and usability of UCMS cells in cancer gene therapy. Thus, UCMS cells can potentially be used for targeted delivery of cancer therapeutics.

Download full-text


Available from: Frank C Marini, Sep 05, 2014
1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Hearing is one of our main sensory systems and having a hearing disorder can have a significant impact in an individual's quality of life. Sensory neural hearing loss (SNHL) is the most common form of hearing loss; it results from the degeneration of inner ear sensory hair cells and auditory neurons in the cochlea, cells that are terminally differentiated. Stem cell-and gene delivery-based strategies provide an opportunity for the replacement of these cells. In recent years, there has been an increasing interest in gene delivery to mesenchymal stem cells. In this study, we evaluated the potential of human umbilical cord mesenchymal stromal cells (hUCMSCs) as a possible source for regenerating inner ear hair cells. The expression of Atoh1 induced the differentiation of hUCMSCs into cells that resembled inner ear hair cells morphologically and immunocytochemically, evidenced by the expression of hair cell-specific markers. The results demonstrated for the first time that hUCMSCs can differentiate into hair cell-like cells, thus introducing a new potential tissue engineering and cell transplantation approach for the treatment of hearing loss.
    02/2013; 15(1):43-54. DOI:10.1089/cell.2011.0097
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Foetal stem cells (FSCs) can be isolated during gestation from many different tissues such as blood, liver and bone marrow as well as from a variety of extraembryonic tissues such as amniotic fluid and placenta. Strong evidence suggests that these cells differ on many biological aspects such as growth kinetics, morphology, immunophenotype, differentiation potential and engraftment capacity in vivo. Despite these differences, FSCs appear to be more primitive and have greater multi-potentiality than their adult counterparts. For example, foetal blood haemopoietic stem cells proliferate more rapidly than those found in cord blood or adult bone marrow. These features have led to FSCs being investigated for pre- and post-natal cell therapy and regenerative medicine applications. The cells have been used in pre-clinical studies to treat a wide range of diseases such as skeletal dysplasia, diaphragmatic hernia and respiratory failure, white matter damage, renal pathologies as well as cancers. Their intermediate state between adult and embryonic stem cells also makes them an ideal candidate for reprogramming to the pluripotent status.
    Journal of The Royal Society Interface 12/2010; 7 Suppl 6:S689-706. DOI:10.1098/rsif.2010.0347.focus · 3.86 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Mesenchymal stem cells (MSCs) are cells of stromal origin that have now been isolated from a wide variety of adult tissues as well as from tissues involved in fetal growth and development, including umbilical cord blood, Wharton’s jelly, amniotic fluid, and placenta. Originally characterized as supporting bone marrow stromal cells, MSCs are now recognized to have a broad range of activities, including the ability to differentiate into a wide variety of adult cell types as well as to have potent immunomodulatory properties. As such, they are increasingly being investigated for use in lung diseases. Initial focus was on structural engraftment and repair of diseased or injured lung. More recent areas of research include use of MSCs for ex vivo three-dimensional lung tissue engineering and for use in immunomodulation of inflammatory and immune-mediated lung diseases. MSCs may also serve as cellular delivery vehicles for lung and other cancers. However, the MSC field is complicated by lack of consistent approaches in both cell isolation and culture as well as in nomenclature. Further, it is unclear whether MSCs obtained from different tissue sources have comparable properties. The long-term tumorigenic potential of MSC administration in humans also remains unclear. Nonetheless, a current clinical trial investigating the safety and potential efficacy of systemic administration of MSCs in patients with chronic obstructive pulmonary disease demonstrates the potential for therapeutic use of MSCs for a range of lung diseases.